Le Lézard
Classified in: Health, Science and technology, Covid-19 virus
Subjects: Photo/Multimedia, Conference, Product/Service, Trade Show

Prestige Biopharma Group to Exhibit at CPhI Frankfurt 2022


Prestige Biopharma group comprised of Prestige Biopharma Limited (950210: KRX) and Prestige Biologics Co., Ltd. (334970: KOSDAQ) is pleased to announce that it will be appearing at CPhI Frankfurt 2022 on 1-3 November at Messe Frankfurt, Germany.

The Prestige group will showcase its latest antibody drug pipeline and innovative CDMO service at a large-scale independent booth, which will be located in BioProduction Zone, #91G10. At the booth, clients and visitors are invited to take part in the experience zones and a transparent OLED display will be exhibited to highlight the EU-GMP certified facility and 154,000 liters of global-scale production capacity of Prestige Biologics in South Korea.

"We are excited to provide an inside look into Prestige Biopharma group at CPhI 2022 and are looking forward to having meaningful partner discussions. We will be introducing our capabilities for development and manufacturing of antibody and vaccine therapeutics, to support our partners to bring life-saving medicines to the patient," said Dr. Michael Ruppert, head of global business development of Prestige Biopharma.

At CPhI Frankfurt 2022, Prestige Biopharma introduces its first-in-class mAb, PBP1510 (INN: ulenistamab) anti-PAUF for pancreatic cancer that recently obtained FDA approval for Phase 1/2a IND and orphan designation from FDA, EMA and Korea MFDS. The company's rich portfolio of biosimilars in various stages including HD201 trastuzumab under marketing authorization review, HD204 bevacizumab in Phase 3 and PBP1502 adalimumab in Phase 1 and others, is aimed to provide affordable quality medicines to those who need. Prestige's business also includes alliance vaccine development and production, starting with the partnered commercial production of COVID-19 vaccines.

Together with Prestige Biologics, the Prestige group has full value chain technological capability, from discovery and development to manufacturing. Prestige Biologics is a leading Korean biopharmaceutical CDMO with 154,000 liters of top-notch production facility that provides efficient and high-quality complete solutions to development and manufacturing requirements throughout drug development continuum from the early-stage concept of clinical biopharmaceuticals through to full, global commercialization of products. Prestige Biologics also provides a customized engineering solution called ?CDEMO' service and it includes process optimization engineering, productivity enhancement engineering and cost reduction engineering.

Prestige Biopharma group will continue to pursue ?innovation for life' in every area which is the group's business purpose, while ensuring corporate DNA, innovation, efficiency and agility, to ultimately create a difference for humanity.

The Prestige group looks forward to the on-site collaboration with biopharmaceutical partners at CPhI Frankfurt 2022. For more information, please visit www.prestigebio.com.


These press releases may also interest you

at 16:10
Gilead Sciences, Inc. announced today that its executives will be speaking at the following investor conferences: SVB Securities Global Biopharma Conference on Tuesday, February 14 at 11:20 AM Eastern Time Cowen Annual Health Care Conference on...

at 16:10
Horizon Therapeutics plc : RECOMMENDED CASH OFFER for HORIZON THERAPEUTICS PLC by Pillartree Limited, a newly formed private limited company wholly owned by Amgen Inc. to be implemented by way of a scheme of arrangement under Chapter 1 of Part...

at 16:10
Junior R. King, DPM, is being recognized by Continental Who's Who as a Distinguished Healthcare Provider for his contributions to the medical field. Dr. King graduated with a medical degree from the Temple University School of Podiatric Medicine, a...

at 16:05
Bright Minds Biosciences Inc. ("Bright Minds" or the "Company") announces that it has received a notification letter (the "Notification Letter") from the Nasdaq Stock Market LLC ("NASDAQ") dated January 26, 2023, notifying the Company that due to...

at 16:05
Inhibikase Therapeutics, Inc. ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases...

at 16:05
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION FOR IMMEDIATE RELEASE...



News published on 27 october 2022 at 01:50 and distributed by: